Reducing self-stigma among survivors of childhood maltreatment: Randomized controlled trial of a brief video intervention.

Objective: Survivors of childhood maltreatment (CM) often experience self-stigma, the internalization of negative attitudes such as shame, self-blame, and a reluctance to disclose their experiences. These self-perceptions pose a significant barrier to treatment-seeking and may exacerbate psychiatric distress. Prior research indicates that social contact-based interventions are effective in reducing stigma, but no study to date has examined their impact on self-stigma and increasing openness to treatment-seeking among CM survivors.

Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal.

Using joint genomic-transcriptomic analysis of 243 samples, we reveal recurrent patterns of nongenetic evolution in ccRCC not exclusively governed by genetic factors, including T-cell depletion, tumor T-cell receptor coevolution, potential cGAS-STING repression, and increased cell proliferation. These patterns can aid clinical management and guide novel treatment approaches.

Biomarkers.

Background: Glial fibrillary acidic protein (GFAP) is a putative blood biomarker for Alzheimer's disease (AD). Most studies measure plasma GFAP (pGFAP) utilizing the Single Molecule Array (Simoa) platform or other high-cost platforms. However, we aim to validate the value of GFAP as a blood biomarker for AD using chemiluminescent microparticle immunoassay (CMIA), an ubiquitous lower-cost platform.

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds.

Forkhead box L2 (FOXL2) encodes a transcription factor essential for sex determination, and ovary development and maintenance. Mutations in this gene are implicated in syndromes involving premature ovarian failure and granulosa cell tumors (GCTs). This rare cancer accounts for less than 5% of diagnosed ovarian cancers and is causally associated with the FOXL2 c.

Tracking non-genetic evolution from primary to metastatic ccRCC: TRACERx Renal.

While the key aspects of genetic evolution and their clinical implications in clear cell renal-cell carcinoma (ccRCC) are well-documented, how genetic features co-evolve with the phenotype and tumor microenvironment (TME) remains elusive. Here, through joint genomic-transcriptomic analysis of 243 samples from 79 patients recruited to the TRACERx Renal study, we identify pervasive non-genetic intratumor heterogeneity, with over 40% not attributable to genetic alterations. By integrating tumor transcriptomes and phylogenetic structures, we observe convergent evolution to specific phenotypic traits, including cell proliferation, metabolic reprogramming and overexpression of putative cGAS-STING repressors amid high aneuploidy.